logo

Saw Palmetto
for
Benign
Prostatic
Hyperplasia
(BPH)

By David Mendosa

Drawing of Saw Palmetto


Saw palmetto has long been used in Europe to treat an enlarged prostate or benign prostatic hyperplasia (BPH). American use lags far behind Europe in part because Americans are not aware of the extensive European research on the herb, some of which is presented here. The most cited journal article is an early (1984) "letter to the editors" by G. Champault et al. American physicians generally don't prescribe any drug other than Finasteride (Proscar®), Terazosin HCI (Hytrin®), or Doxazosin mesylate (Cardura®) for BPH. But unlike these drugs, particularly Proscar®, saw palmetto usually kicks in quickly. With the saw palmetto extract most men achieve some relief of symptoms within the first 30 days.

Saw palmetto is, according to industry sources that I trust, one species with several different names, including Serenoa repens, Serenoa serrulata, and sabal. The industry is attempted to standardize on the name Serenoa repens, which is the way most research identifies it.

Florida is the biggest producer of saw palmetto. Small patches can be found from the southeast coastline of South Carolina and southeastern Georgia to southern Mississippi. But it does not grow naturally in Texas, Mexico, or the Caribbean. It grows in every Florida county, but much of its production centers in South Florida.

The Associated Press reported on recent saw palmetto developments in Florida in an article extracted here.

In 1994 an important entrant joined this growing field. It's called the Saw Palmetto Berries Co-op of Florida, Inc. Headed by CEO Gregory P. Zaino, this company can harvest more than 3 millions pounds of berries annually. Based in Naples, Florida, Mr. Zaino can be reached at (239) 775-1243. The Naples Daily News had a two-page cover story in its August 25, 1996, issue about Mr. Zaino and his operation. You can read it here at http://www.mendosa.com/vachon.htm. The article was written by Staff Business Writer Michelle Vachon, who happens to be an old friend and associate of mine from when we worked together as editors of a magazine years ago.

New Research Report

A long-term study of 150 men with clinically diagnosed BPH and complaints of prostatic symptoms has demonstrated "the long-term efficacy and tolerability of Permixon and support its use as a first-line medical therapy for uncomplicated symptomatic BPH." Permixon is a brand of standardized saw palmetto extract sold widely in Europe. The abstract of this study conducted by the Scientific Research Institute of Urology, Moscow, Russia, appeared in the November-December 2002 issue of Advances in Therapy, and is online at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12665050&dopt=Abstract.

The study's conclusions are impressive:

At 6, 12, 18, and 24 months, the International Prostate Symptom Score (I-PSS), quality of life, and sexual function score were recorded, and urodynamics and biologic values were measured. Adverse events were recorded every 3 months. I-PSS and quality of life improved significantly from baseline at each evaluation time point. At the end of the study and at each evaluation, maximum urinary flow also improved significantly. Prostate size decreased. Sexual function remained stable during the first year of treatment and significantly improved (P = .001) during the second year. Prostate-specific antigen was not affected, and no changes in plasma hormone levels were observed. Nine patients reported 10 adverse events, none related to treatment. Improvements in efficacy parameters began at 6 months and were maintained up to 24 months.

The Saw Palmetto Harvesting Company in Frostproof, Florida, is a broker of saw palmetto. Gerald W. Gettel is a pharmacist and the company's president. Especially interesting is a comparison of "Saw palmetto extract vs. Proscar" at http://www.sawpalmetto.com/proscar.html. The company's home page is http://www.sawpalmetto.com/.

I use saw palmetto myself with impressive results. I have, unfortunately, no financial interest in saw palmetto and am a freelance journalist, rather than a medical doctor. Therefore, I cannot vouch for or evaluate the claims made by others.

There are still many questions about saw palmetto in my mind, even though I know from experience that it works for me. How can we determine which brands are reliable? Should we be concerned with manufacturing methods such as extraction using the so-called "toxic solvent hexane or preferably [the more expensive] supercritical carbon dioxide"? And what about freeze-drying? And are there synergies from taking a combination of saw palmetto and Pygeum africanum? Any answers or even leads to answers will be most appreciated and shared as appropriate.

As valuable as saw palmetto is you should not consider it alone for BPH. There is also some evidence suggesting that a low-fat diet, zinc supplements, and essential fatty acids (from sources such as flax oil) and another herb, Pygeum africanum, are useful for treating BPH. Some warn that men with BPH should avoid alcohol. You should also be sure to consult an M.D., especially for a prostate-specific antigen (PSA) test and a digital rectal examination (DRE) to rule out prostate cancer.

Note that there are many more Web sites than those listed here that offer you saw palmetto for sale. I list these sites in the order in which I discovered them. Only those sites that I think offer significant information are listed below.

The recent study by Dr. Johan Braeckman (see below) is the most comprehensive yet of saw palmetto.

A. Saw Palmetto and PSA Tests

A concern about self-medication with saw palmetto was raised by a urologist, Arnaldo F. Trabucco of the Catholic Medical Center of Brooklyn & Queens, New York, in several postings on mailing lists and Usenet newsgroups. He also has a Web site, the Trabucco Urology Institute in Rego Park, New York, at http://www.institute-md.com. Dr. Trabucco warns that men must get a baseline PSA level before taking saw palmetto, since it can decrease prostate cancer detection by interfering with PSA levels.

However, a recent study conducted by Leonard S. Marks, M.D., of the Urological Sciences Research Foundation in California, contradicts Dr. Trabucco's claim. Dr. Marks writes:

"We have conducted a randomized clinical trial, presented at the Annual Meeting of the American Urological Association last May, showing clearly that saw palmetto does not affect the serum PSA levels (either total, free, or % free). But you'd better check the other ingredients in the preparation you're taking. I can only speak for what we tested, which was saw palmetto, plus the other contents shown in the data slides mentioned below.

Dr. Marks added:

"Please feel free to use these comments any way you wish. We stand solidly behind the data shown on the PowerPoint presentation at http://www.usrf.org/auaslides/index.htm Incidentally, two very large studies done prior to ours (the Wilt meta-analysis reported in J.A.M.A. and the Carraro study published in Prostate) also showed no effect of saw palmetto on serum PSA levels. We are continuing to follow our patients, and an 18 month analysis is in progress at this time."

A report in the July 1994 issue of Current Therapeutic Research by Dr. Johan Braeckman of the Department of Urology, University of Brussels in Brussels, Belgium, was the first to determine that saw palmetto—unlike Finasteride (Proscar®)—will not give misleadingly low PSA levels. His study is called "The Extract of Serenoa Repens in the Treatment of Benign Prostatic Hyperplasia: A Multicenter Open Study." In 1992 and 1993 some 112 urologists enrolled 505 patients with BPH into a 90-day study, of whom 16 dropped out and an additional 184 did not fulfilled all inclusion criteria, leaving 305 patients for whom they could evaluate the efficacy of a standardized saw palmetto extract.

"Because administration of finasteride is accompanied by significant decreases in PSA levels (about 50% with a 5-mg dose), this treatment carries the risk of masking the development of prostate cancer during treatment," Dr. Braeckman writes on page 782. "Our study clearly demonstrated the absence of such a risk with the administration of Serenoa repens extract, as the agent does not modify the serum PSA concentration. The clinical implications of this conservative effect on PSA levels remains to be determined."

Here are other important findings from the study: